Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation
CompletedNot applicableNCT00060021
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
RATIONALE: Acupuncture may be effective in relieving mucositis-related pain caused by chemotherapy in patients undergoing stem cell transplantation. PURPOSE: Randomized clinical trial to study the effectiveness of acupuncture in treating mucositis-related pain caused by high-dose chemotherapy in patients who are undergoing stem cell transplantation.
Study details
- Official title
- A Randomized, Placebo-Controlled, Blinded Study Of Acupuncture Therapy In Mucositis-Related Pain In Patients Undergoing Hematopoietic Stem Cell Transplantation
- Conditions
- Interventions
- Procedure: acupuncture therapy
- Procedure: management of therapy complications
- Procedure: pain therapy
- Sponsor
- National Cancer Institute (NCI)
- Start date
- 2003-03
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
DISEASE CHARACTERISTICS: * Must be undergoing hematopoietic stem cell transplantation (HSCT) through one of the following means: * Concurrent enrollment on a HSCT protocol with the Experimental Transplantation \& Immunology Branch (ETIB) at the NCI Center for Clinical Research\* * Receiving HSCT as a compassionate exemption following the clinical guidelines of an ETIB protocol\* * Directly observed oral or pharyngeal mucositis and/or suspected esophageal mucositis after high-dose chemotherapy * No pain unrelated to mucositis requiring use of potent analgesics prior to initiation of high-dose chemotherapy NOTE: \*Protocol must be known to generate more than 50% incidence of high-dose chemotherapy-induced mucositis PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Not specified Life expectancy * Not specified Hematopoietic * No history of bleeding disorders Hepatic * PT and PTT normal Renal * Not specified Other * No history or evidence of drug addiction or drug-seeking behavior * No skin infection at the sites of acupuncture points PRIOR CONCURRENT THERAPY: Biologic therapy * See Disease Characteristics Chemotherapy * See Disease Characteristics Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified Other * No concurrent anticoagulant therapy
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00060021